Aug. 18 at 7:11 PM
$BHVN
In Vkad I trust cause Mr Coric (
$BHVN) operates with a distinct focus on business execution, scientific data, and capital strategy. Rather than engaging in public disputes over market price action, he prioritizes scaling the pipeline and maintaining institutional backing.
Proven Execution Track Record: Coric previously built and sold Biohaven’s CGRP portfolio to Pfizer for ~
$11.6B. That history gives him strong credibility with institutional investors when advancing new programs.
Diversified Pipeline Approach: Instead of depending on a single binary outcome, Biohaven maintains multiple platform shots on goal—including Kv7 ion channel modulators, extracellular protein degraders (MoDEs), and myostatin inhibitors.
Pragmatic Adaptation: Following regulatory friction (such as the CRL for troriluzole), the management team adjusted by reallocating capital, trimming late-stage R&D costs, and shifting resources toward high-conviction clinical priorities.
